Coronavirus | Covovax trials begin in India, hope to launch it by September 2021: Adar Poonawalla
The Hindu
The vaccine is made through a partnership with America’s Novavax and Serum Institute of India
Serum Institute of India (SII) CEO Adar Poonawalla on Saturday said clinical trials of COVID-19 vaccine Covovax have begun in India and the company hopes to launch it by September this year. In August 2020, American vaccine company Novavax, Inc had announced a licence agreement with SII for the development and commercialisation of NVX-CoV2373, its COVID-19 vaccine candidate, in low and middle-income countries and India. "Covovax trials finally begin in India; the vaccine is made through a partnership with @Novavax and @SerumInstIndia. It has been tested against African and UK variants of #COVID19 and has an overall efficacy of 89%. Hope to launch by September 2021!," Mr Poonawalla said in a tweet.More Related News

Madras High Court quashes criminal case against Leela Samson, Bharatanatyam dancer and former director of Kalakshetra Foundation, after she settles matter by paying ₹8 lakh to the complainant, a female dance intern, whom she had described as the “mistress” of a male faculty member in her Facebook post.












